drugset / Trial / NCT06474455
A Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is an open-label, multicenter Phase IB/II clinical trial to evaluate the safety, tolerability and efficacy of SHR-9839 for injection in combination with other antitumor therapies in patients with advanced solid tumors.
Timeline
- Start
- 2024-07-02
- Primary completion
- 2029-06
- Completion
- 2029-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SHR-9839 | Unknown | — | Subcutaneous |
| Background | Adebrelimab | Monoclonal antibody | — | — |
| Background | Almonertinib | Small molecule | — | — |
| Background | Carboplatin | Small molecule | — | — |
| Background | Paclitaxel | Small molecule | — | — |
| Background | Pemetrexed | Small molecule | — | — |
| Background | SHR-A1921 | Monoclonal antibody | — | — |
| Background | SHR-A2009 | Other / unclassified | — | — |